Medscape |
---|
'Exciting Time for NASH' With Resmetirom Phase 3 Results |
![]() VIENNA — Resolution of non-alcoholic steatohepatitis (NASH), and reduction of fibrosis on liver biopsy were achieved with the oral, thyroid hormone receptor beta-selective agonist resmetirom (Madrigal Pharmaceuticals) in patients with NASH and associated cirrhosis in a pivotal phase 3 clinical trial. The primary results of the MAESTRO-NASH (NCT03900429) trial were reported here at the European Association for the Study of the Liver (EASL) Congress 2023. |
||
2023-06-22 Read more about this article in source |
-
The ‘Six Pillars of Brain Health’ offers a game plan to maintain cognitive function 04/25/2025
-
Avocados, cheese and nuts are high in calories but have big health benefits 04/25/2025
-
Perfecting the squat before trying a lunge can start you off on the right foot 04/25/2025